Abraxis BioScience (ABII)

Market for Common Stock

Our common stock is listed and traded on The NASDAQ Global Market under the symbol “ABII.” Regular-way trading of our common stock commenced on November 14, 2007, the day after our separation from Old Abraxis. The following table sets forth the prices for our common stock as reported by NASDAQ for fiscal years 2009 and 2008:

As of February 26, 2010, there were approximately 68 stockholders of record of our common stock and the closing price of our stock as reported by NASDAQ on that date was $32.35.

Market for Common Stock

Our common stock is listed and traded on The Nasdaq Global Market under the symbol “ABII.” Regular-way trading of our common stock commenced on November 14, 2007, the day after our separation from Old Abraxis. The following table sets forth the prices for our common stock as reported by NASDAQ for fiscal years 2008 and 2007:

(a) No trading occurred prior to November 14, 2007. Figures for the quarter ended December 31, 2007 are as reported on Nasdaq between November 14, 2007 and December 31, 2007.

As of February 24, 2009, there were approximately 70 stockholders of record of our common stock and the closing price of our stock as reported by NASDAQ on that date was $73.01.

Market for Common Stock

Our common stock is listed and traded on The Nasdaq Global Market under the symbol “ABII.” Regular-way trading of our common stock commenced on November 14, 2007, the day after our separation from Old Abraxis. The low and high prices of our common stock between November 14, 2007 and December 31, 2007 as reported on Nasdaq were $38.15 and $71.72, respectively.

As of March 20, 2008, there were approximately 75 stockholders of record of our common stock and the closing price of our stock as reported by the NASDAQ on that date was $61.05.

Market for Our Common Stock

There is no existing market for our common stock. However, our common stock has been approved for listing on the Nasdaq Global Market under the symbol “ABII.” The New APP common stock will trade on the Nasdaq Global Market under the symbol “APPX” following the separation and distribution. We expect that a “when-issued” trading market for our common stock will develop on or shortly before the record date. The term “when-issued” means that shares can be traded prior to the time certificates are actually available or issued. On the first trading day following the distribution date, when-issued trading in our common stock will end and “regular-way” trading will begin. Regular-way trading refers to trading after a security has been issued and typically involves a transaction that settles on the third full business day following the date of a transaction.

There can be no assurance about the trading prices for our common stock before or after the distribution date and, until the common stock is fully distributed and an orderly market develops, the trading prices for these securities may fluctuate. Prices for our common stock will be determined in the trading markets and may be influenced by many factors, including the depth and liquidity of the market for such securities, developments generally affecting our business, the impact of the factors referred to in “Risk Factors,” investor perceptions of our company and our business and operating results, our dividend policy, and general economic and market conditions.

Shares of our common stock distributed to Abraxis BioScience stockholders in the distribution will be freely transferable under the Securities Act of 1933, as amended, which we refer to as the Securities Act, except for shares received by persons who may be deemed to be our affiliates. Persons who may be deemed to be our affiliates after the distribution generally include individuals or entities that control, are controlled by, or are under common control with us and may include our officers, directors and principal stockholders. After we become a publicly-traded company, securities held by persons who are our affiliates will be subject to resale restrictions under the Securities Act. Our affiliates will be permitted to sell shares of the entity of which such persons are affiliates only pursuant to an effective registration statement or an exemption from the registration requirements of the Securities Act, such as the exemption afforded by Rule 144 under the Securities Act. Certain of our affiliates have been granted registration rights requiring us to register their shares of our common stock. See “Certain Relationships and Related Transactions—Registration Rights.”

Our transfer agent and registrar will be American Stock Transfer & Trust Company.